DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Sutent (Sunitinib Malate) - Current Clinical Trials

 
 



Sutent Related Clinical Trials

Sutent Adjunctive Treatment of Differentiated Thyroid Cancer [Active, not recruiting]

A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma [Terminated]

A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma [Completed]

Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma [Active, not recruiting]

CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer [Recruiting]

Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors [Completed]

Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors [Terminated]

A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma [Completed]

Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer [Active, not recruiting]

Pre-Surgical Sutent in Renal Cell Carcinoma (RCC) [Active, not recruiting]

Study In Patients With Kidney Cancer Treated With Sutent [Completed]

Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENTŪ [Completed]

Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer [Completed]

Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow [Terminated]

Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC) [Completed]

SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer [Completed]

Study of SutentŪ/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas [Suspended]

A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma [Terminated]

Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer [Completed]

The Influence of Phenotype, Grapefruit Juice and Orange Juice on the Pharmacokinetics of Sunitinib in Cancer Patients [Completed]

Study of SU11248 in Men With Advanced Prostate Cancer [Completed]

Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy [Terminated]

Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule [Active, not recruiting]

Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue Sarcoma [Completed]

Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma [Completed]

Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer [Completed]

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma [Active, not recruiting]

Sunitinib Malate in Refractory Germ Cell Tumors [Terminated]

A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands [Completed]

Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer [Completed]

Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma [Active, not recruiting]

Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma [Withdrawn]

Evaluation of Patients With Bulky GIST Using Sunitinib [Active, not recruiting]

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) [Active, not recruiting]

Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC) [Recruiting]

Sutent Rechallenge In mRCC Patients [Completed]

Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma [Completed]

Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic or Unresectable Kidney Cancer [Active, not recruiting]

Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy [Terminated]

SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme [Active, not recruiting]

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma [Completed]

Treatment Protocol for Patients Continuing From SU011248 Protocols [Completed]

A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma. [Recruiting]

Sunitinib Non Small Cell Lung Cancer Patients Over 70 [Completed]

Ph I SU011248 + Irinotecan in Treatment of Pts w MG [Completed]

Temodar and Sutent as Therapy for Melanoma [Terminated]

SUTENTŪ In The First Line Treatment Of Renal Cell Carcinoma [Completed]

Capiri-sutent Phase-1 in Advanced Colo-rectal Cancer [Recruiting]

Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases [Completed]

Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma [Recruiting]

Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization [Completed]

Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery [Completed]

Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy [Completed]

Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma [Completed]

Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy [Completed]

Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer [Completed]

SU011248 in Advanced Hepatocellular Carcinoma [Completed]

Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer [Active, not recruiting]

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients [Recruiting]

Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years [Completed]

A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma [Recruiting]

Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy [Active, not recruiting]

Study of Safety and Effects of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma [Terminated]

Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients [Terminated]

A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor [Recruiting]

Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC) [Recruiting]

Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer [Completed]

Phase II Study of Alternating Sunitinib and Temsirolimus [Recruiting]

A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma [Completed]

Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma [Terminated]

Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma [Terminated]

A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors [Completed]

Exemestane With Sunitinib (SUTENTŪ) in Metastatic Breast Cancer [Terminated]

Sunitinib and Capecitabine for First Line Colon Cancer [Terminated]

Bevacizumab and Sunitinib in Treating Patients With Solid Tumors [Completed]

A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together [Completed]

IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma [Completed]

Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer [Active, not recruiting]

A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors [Completed]

Clinical Trial of Sutent to Treat Metastatic Melanoma [Completed]

Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies [Completed]

SunitinibŪ in Patients With Recurrent Ovarian Clear Cell Carcinoma [Recruiting]

Sutent + Taxol for Advanced Esophageal Cancer [Completed]

Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck [Terminated]

A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone [Completed]

Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive [Completed]

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy [Active, not recruiting]

Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors [Completed]

Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer [Completed]

Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma [Completed]

Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy [Completed]

Erlotinib and Sunitinib in NSCLC [Completed]

Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors [Recruiting]

An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer [Completed]

Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors. [Recruiting]

A Retrospective Real World Analysis Of Sutent In Patients With Metastatic Renal Cell Carcinoma In Community And Academic Centers To Assess The Impact Of Dose Variation On Duration Of Response And Overall Survival [Completed]

Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases [Terminated]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017